SG11202108312PA - Method of safe administration of phosphorylated tau peptide vaccine - Google Patents
Method of safe administration of phosphorylated tau peptide vaccineInfo
- Publication number
- SG11202108312PA SG11202108312PA SG11202108312PA SG11202108312PA SG11202108312PA SG 11202108312P A SG11202108312P A SG 11202108312PA SG 11202108312P A SG11202108312P A SG 11202108312PA SG 11202108312P A SG11202108312P A SG 11202108312PA SG 11202108312P A SG11202108312P A SG 11202108312PA
- Authority
- SG
- Singapore
- Prior art keywords
- peptide vaccine
- phosphorylated tau
- tau peptide
- safe administration
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962802870P | 2019-02-08 | 2019-02-08 | |
| PCT/US2020/017235 WO2020163730A2 (en) | 2019-02-08 | 2020-02-07 | Method of safe administration of phosphorylated tau peptide vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202108312PA true SG11202108312PA (en) | 2021-08-30 |
Family
ID=69780323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202108312PA SG11202108312PA (en) | 2019-02-08 | 2020-02-07 | Method of safe administration of phosphorylated tau peptide vaccine |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11684576B2 (de) |
| EP (1) | EP3920966A2 (de) |
| JP (1) | JP2022520060A (de) |
| KR (1) | KR20210125048A (de) |
| CN (1) | CN113710269A (de) |
| AU (1) | AU2020219804A1 (de) |
| BR (1) | BR112021014794A2 (de) |
| CA (1) | CA3129252A1 (de) |
| EA (1) | EA202192203A1 (de) |
| IL (1) | IL285163A (de) |
| JO (1) | JOP20210211A1 (de) |
| MX (1) | MX2021009508A (de) |
| SG (1) | SG11202108312PA (de) |
| TW (1) | TW202045204A (de) |
| WO (1) | WO2020163730A2 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA50465A (fr) * | 2017-10-25 | 2020-09-02 | Ac Immune Sa | Compositions de peptides tau phosphorylés et leurs utilisations |
| CA3152239A1 (en) * | 2019-09-23 | 2021-04-01 | Lars Ittner | Treatment of tauopathies |
| GB2600468A (en) * | 2020-10-30 | 2022-05-04 | Excivion Ltd | Adjuvant composition |
| AU2022328342A1 (en) * | 2021-08-12 | 2024-02-22 | Ac Immune Sa | Liposomes containing phosphorylated tau peptides for inducing sustained immune responses |
| WO2023023332A1 (en) * | 2021-08-20 | 2023-02-23 | Thomas Jefferson University | Monophosphoryl lipid adjuvant (mpla) compositions, vaccine compositions thereof, and methods of preparing and using the same |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5811310A (en) | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
| JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
| US7408027B1 (en) | 1991-12-06 | 2008-08-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften | Tools for the diagnosis and treatment of Alzheimer's disease |
| ES2118373T3 (es) | 1992-12-14 | 1998-09-16 | Innogenetics Nv | Anticuerpos monoclonales dirigidos contra la proteina tau asociada a microtubulos, hibridomas que segregan estos anticuerpos, reconocimiento de antigenos por estos anticuerpos monoclonales y sus aplicaciones. |
| US7427392B1 (en) | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
| US20020086009A1 (en) | 1996-03-13 | 2002-07-04 | Koichi Ishiguro | Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same |
| WO1998022120A1 (en) | 1996-11-19 | 1998-05-28 | The Wistar Institute Of Anatomy & Biology | Diagnostic and therapeutic reagents for alzheimer's disease |
| EP1301531A2 (de) | 2000-07-11 | 2003-04-16 | Molecular Geriatrics Corporation | Screeningsverfahren und verbindungen dafur |
| GB0114719D0 (en) * | 2001-06-15 | 2001-08-08 | Glaxo Group Ltd | Compound |
| AU2003203079B9 (en) | 2002-02-04 | 2009-01-15 | Oncothyreon Inc. | Immunostimulatory, covalently lipidated oligonucleotides |
| MXPA04010255A (es) * | 2002-04-19 | 2008-03-04 | Univ Toronto | Metodos inmunologicos y composiciones para el tratamiento de la enfermedad de alzheimier. |
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| US20050261475A1 (en) | 2004-02-13 | 2005-11-24 | Harvard Medical School | Solid-phase capture-release-tag methods for phosphoproteomic analyses |
| WO2005080986A1 (en) | 2004-02-18 | 2005-09-01 | University Of Iowa Research Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
| CN101330923B (zh) | 2005-12-12 | 2015-01-07 | Ac免疫有限公司 | 治疗性疫苗 |
| WO2007068105A1 (en) | 2005-12-12 | 2007-06-21 | Robarts Research Institute | Method of diagnosing amyotrophic lateral sclerosis |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| WO2008140639A2 (en) | 2007-02-08 | 2008-11-20 | Oligomerix, Inc. | Biomarkers and assays for alzheimer's disease |
| EP2210901A4 (de) | 2007-10-19 | 2012-04-25 | Immunas Pharma Inc | Zur spezifischen bindung an ein oligomer fähiger antikörper, und dessen verwendung |
| PT2408807T (pt) | 2009-03-18 | 2021-09-03 | Ac Immune Sa | Processo para utilização terapêutica |
| UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| EP2440234A4 (de) | 2009-06-10 | 2013-11-06 | Univ New York | Immunologische anzielung pathologischer tau-proteine |
| WO2011013034A1 (en) | 2009-07-30 | 2011-02-03 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
| EP3527220A1 (de) | 2010-08-12 | 2019-08-21 | AC Immune S.A. | Manipulation von impfstoffen |
| WO2012055933A1 (en) | 2010-10-26 | 2012-05-03 | Ac Immune S.A. | Liposome-based construct comprising a peptide modified through hydrophobic moieties |
| NZ630610A (en) | 2014-02-14 | 2019-05-31 | Ipierian Inc | Tau peptides, anti-tau antibodies, and methods of use thereof |
| KR20170023151A (ko) | 2014-06-26 | 2017-03-02 | 얀센 백신스 앤드 프리벤션 비.브이. | 미세소관-연관 단백질 타우에 특이적으로 결합하는 항체 및 항원-결합 단편 |
| JP6793134B2 (ja) | 2015-06-05 | 2020-12-02 | ジェネンテック， インコーポレイテッド | 抗ｔａｕ抗体及び使用方法 |
| AR110321A1 (es) | 2016-12-07 | 2019-03-20 | Genentech Inc | Anticuerpos antitau y métodos de uso |
| MA50465A (fr) | 2017-10-25 | 2020-09-02 | Ac Immune Sa | Compositions de peptides tau phosphorylés et leurs utilisations |
| EP3706795A4 (de) | 2017-11-09 | 2021-10-13 | Pinteon Therapeutics Inc. | Verfahren und zusammensetzungen zur erzeugung und verwendung von humanisierten konformationsspezifischen phosphorylierten tau-antikörpern |
| BR112021021213A2 (pt) | 2019-04-24 | 2021-12-21 | Ac Immune Sa | Administração heteróloga de vacinas de tau |
-
2020
- 2020-02-07 CA CA3129252A patent/CA3129252A1/en active Pending
- 2020-02-07 MX MX2021009508A patent/MX2021009508A/es unknown
- 2020-02-07 BR BR112021014794-2A patent/BR112021014794A2/pt unknown
- 2020-02-07 JP JP2021546263A patent/JP2022520060A/ja active Pending
- 2020-02-07 US US16/785,011 patent/US11684576B2/en active Active
- 2020-02-07 SG SG11202108312PA patent/SG11202108312PA/en unknown
- 2020-02-07 KR KR1020217028336A patent/KR20210125048A/ko active Search and Examination
- 2020-02-07 CN CN202080027380.1A patent/CN113710269A/zh active Pending
- 2020-02-07 EA EA202192203A patent/EA202192203A1/ru unknown
- 2020-02-07 AU AU2020219804A patent/AU2020219804A1/en active Pending
- 2020-02-07 EP EP20710370.6A patent/EP3920966A2/de active Pending
- 2020-02-07 WO PCT/US2020/017235 patent/WO2020163730A2/en unknown
- 2020-02-07 JO JOP/2021/0211A patent/JOP20210211A1/ar unknown
- 2020-02-10 TW TW109104093A patent/TW202045204A/zh unknown
-
2021
- 2021-07-27 IL IL285163A patent/IL285163A/en unknown
-
2023
- 2023-05-12 US US18/316,829 patent/US20230381108A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3920966A2 (de) | 2021-12-15 |
| US11684576B2 (en) | 2023-06-27 |
| WO2020163730A3 (en) | 2020-09-24 |
| CN113710269A (zh) | 2021-11-26 |
| JOP20210211A1 (ar) | 2023-01-30 |
| US20230381108A1 (en) | 2023-11-30 |
| JP2022520060A (ja) | 2022-03-28 |
| US20200253873A1 (en) | 2020-08-13 |
| WO2020163730A2 (en) | 2020-08-13 |
| MX2021009508A (es) | 2021-09-08 |
| TW202045204A (zh) | 2020-12-16 |
| IL285163A (en) | 2021-09-30 |
| CA3129252A1 (en) | 2020-08-13 |
| KR20210125048A (ko) | 2021-10-15 |
| AU2020219804A1 (en) | 2021-08-19 |
| EA202192203A1 (ru) | 2021-10-20 |
| BR112021014794A2 (pt) | 2021-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285163A (en) | A method for the safe administration of a phosphorylated tau peptide vaccine | |
| IL272786A (en) | Preparation of therapeutic exosomes using membrane proteins | |
| ZA202100578B (en) | Formulation of a peptide vaccine | |
| SG11202001161YA (en) | Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3 | |
| ZA202108168B (en) | Heterologous administration of tau vaccines | |
| IL267622A (en) | Method for modifying the therapeutic effects of drugs | |
| IL275639A (en) | Formulation for RNA administration | |
| IL272513A (en) | Lyophilization process for pharmaceutical formulation of medical protein | |
| EP3576764A4 (de) | Kras-peptid-impfstoffzusammensetzungen und verfahren zur verwendung | |
| EP3127552A4 (de) | Mikronadelgruppenpräparat mit inaktiviertem vollvirusimpfstoff und verfahren zur verabreichung davon | |
| EP3703817A4 (de) | Orale verabreichung von glp-1-peptidanaloga | |
| IL283286A (en) | Pharmaceutical formulations of cyclosporine analogs | |
| EP3525772A4 (de) | Formulierungen zur enterischen verabreichung von therapeutika | |
| HUE063747T2 (hu) | Eljárás liraglutid elõállítására BAL linker alkalmazásával | |
| EP3371212A4 (de) | Peptide und verfahren zur behandlung von herzstillstand | |
| IL280883A (en) | Systems for enteric delivery of therapeutic agents | |
| IL288550A (en) | Pharmaceutical compositions for fcrn inhibitors for subcutaneous administration | |
| IL282842A (en) | Medicinal compounds for subcutaneous control | |
| GB201812861D0 (en) | Methods of administering therapy | |
| EP3324990A4 (de) | Identifikation von immunogenen mhc-klasse-ii-peptiden für immunbasierte therapie | |
| EP3474826A4 (de) | Pharmazeutische zubereitung zur verabreichung von peptiden und proteinen | |
| EP3466422A4 (de) | Anwendung von z-butylidenphthalid zur stärkung des angeborenen immunsystems | |
| SG11202011004RA (en) | Hepatitis b vaccine transnasal administration system | |
| GB202013912D0 (en) | Single-dose live-attenuated YF17D-vectored vaccine against SARS-CoV-2 | |
| GB202010479D0 (en) | Single-dose live-attenuated YF17D-vectored vaccine against SARS-CoV-2 |